RegMedNet

Part of Taylor & Francis, features the latest news, opinions, insight and more on #regenerativemedicine, #cellandgenetherapy in partnership with @Regen_Med

[RegMedNet @RegMedNet]

As part of our In Focus on stem cells, we put Hagen Wieland, Team leader of Research and Development at PromoCell, in the hot seat to find out his expert tips on tackling variability, scaling processes, and leveraging cryopreservation for robust regenerative therapies >>> https://t.co/JnR4GrXFuq

[RegMedNet @RegMedNet]

⌛Three stories in three minutes >>> https://t.co/sZtorDYneh

Catch up on top cell and gene therapy news on RegMedNet, including:

1️⃣Positive Phase I results for a single-dose base editing therapy for hypercholesterolemia

2️⃣The opening of 14,000-square-foot FDA-compliant manufacturing facility

3️⃣A $50 million investment to establish an advanced biomanufacturing and R&D center in Chicago

[RegMedNet @RegMedNet]

Are you interested in exploring key stages of stem cell therapy development and the critical steps needed to ensure consistency, scalability and functionality throughout the workflow?

Learn more in this infographic, ‘Stem cell therapy: Building reproducible and scalable workflows’! Download now! >>> https://t.co/5IUrbymkRC

[RegMedNet @RegMedNet]

Researchers at the University of California San Diego School of Medicine have developed an experimental gene therapy that may help protect the brain from TDP-43-related proteinopathy – a type of neurodegeneration commonly seen in frontotemporal dementia, Alzheimer's disease and ALS. Read here: https://t.co/6eZQr7AnrY

[RegMedNet @RegMedNet]

What recent advances have been made in the development of xeno‑free and animal component‑free cell culture media? What are the broader industry trends that are shaping their development? Uncover insights from GMP and compliance experts at PromoCell >>> https://t.co/wNXV9LsU2W

[RegMedNet @RegMedNet]

This Saturday is World MS Day 🌍

To mark the day, we reviewed some recent advancements in MS research and examined current and emerging regenerative approaches that hold promise for enhancing treatment options: https://t.co/yJ22yk8Y8b

[RegMedNet @RegMedNet]

Accurate cytokine profiling is essential for evaluating CAR T-cell efficacy and safety, especially for predicting cytokine release syndrome risk. This Application Note from @ThermoFisher shows automated workflows reducing hands-on time from 5+ hours to just 45 minutes. Learn more about automated workflows >>> https://t.co/VzmOdsphlM

[RegMedNet @RegMedNet]

Discover how xeno-free and animal component-free media reduce variability and contamination risks in cell-based therapies. Our Spotlight feature highlights the role of raw materials and supply chain resilience in enabling reproducible, patient-ready therapies >>> https://t.co/46W0bQSqyq

[RegMedNet @RegMedNet]

A new 3D-printed scaffold tray developed by Cincinnati Children’s could help accelerate the production of gut organoids, offering solutions for scalable tissue repair >>> https://t.co/s7IXPnzoX4

[RegMedNet @RegMedNet]

A novel cytokine-armored CAR-T cell therapy has been developed by scientists at the UCLA Health Jonsson Comprehensive Cancer Center, aiming to tackle aggressive brain tumors >>> https://t.co/dsNen0j2vo

[RegMedNet @RegMedNet]

Catch up on the latest news in cell and gene therapy >>> https://t.co/rbciuWaisK

This week:

👉 HaemaLogiX announced the opening of its KOALA Phase I trial that will assess its KMCAR™ T-cell therapy

👉 Elpida Therapeutics and Catalent have announced a strategic partnership to support late-phase manufacturing of Elpida’s lead gene therapy program

👉 Protara Therapeutics has announced positive updated 12-month data from Cohort A of its ongoing Phase II ADVANCED trial evaluating its TARA-002 cell therapy

[RegMedNet @RegMedNet]

🧪 Simplify your reagent selection process! Explore PromoCell’s detailed specifications for human, animal and non-animal-derived components in this guide >>> https://t.co/3Jf8YPtJnw

[RegMedNet @RegMedNet]

Check out our roundup of recent advancements in CAR-T therapy >>> https://t.co/0tEpg8DE8i

Explore the application of CAR-T therapy in hematological cancers, autoimmune diseases, solid tumors and tissue regeneration!

[RegMedNet @RegMedNet]

Survey: share your insights on raw materials and supply chain management for a chance to win a $50 voucher! RegMedNet wants to hear your thoughts on scaling cell therapies >>> https://t.co/dyaG73Jr1F

[RegMedNet @RegMedNet]

Researchers at Tampere University have developed a 3D-printed ceramic implant that closely replicates human bone structure, advancing personalized bone regeneration and potentially enabling more effective, accessible treatments for bone defects >>> https://t.co/BK9jDBrTQM

[RegMedNet @RegMedNet]

Discover how to properly characterize human mesenchymal stem cells (hMSCs) using ISCT's three gold-standard criteria: plastic adherence, specific marker expression and multipotent differentiation potential. View the poster >>> https://t.co/22z55sSn8p

[RegMedNet @RegMedNet]

What happened in March? Get quick insights in Dusko Ilic's monthly industry updates, including an in vivo CRISPR gene-editing therapy for hereditary angioedema: https://t.co/4qEVxbkcEC

[RegMedNet @RegMedNet]

Catch up on the latest news in cell and gene therapy >>> https://t.co/u0mis43sUh

This week:
👉 The UK’s MHRA has launched a nationwide consultation to modernize gene therapy regulation

👉 OrganaBio LLC has acquired Excellos Inc.’s operating assets

👉 Fractyl Health, Inc. has received Clinical Trial Application authorization in the Netherlands to initiate a Phase I/II study of a gene therapy for type 2 diabetes

[RegMedNet @RegMedNet]

Laying the foundations for a robust stem cell workflow

"It is a widespread misconception that post-thaw viability is the most suitable parameter to assess the quality and performance of cryopreservation media” says Hagen Wieland, Team leader of Research and Development at PromoCell. Read the full interview for more >>> https://t.co/QyRyOKK1HP

[RegMedNet @RegMedNet]

Researchers from Utah State University have demonstrated the potential of CRISPR-Cas12a2 to selectively eliminate target cells while minimizing off-target effects >>> https://t.co/zC6LNNvx2Z